Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms

Surgery (United States)

Volumn 152, Issue 1, 2012, Pages 107-113

  Hamilton, Nicholas A ^a   Liu, Ta Chiang ^a   Cavatiao, Antonino ^a   Mawad, Kareem ^a   Chen, Ling ^b   Strasberg, Steven S ^a   Linehan, David C ^a   Cao, Dengfeng ^a   Hawkins, William G ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS RESECTION; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR DIFFERENTIATION; TUMOR VOLUME;

CARCINOMA, NEUROENDOCRINE; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84862881173     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2012.02.011     Document Type: Article

References (11)

1. Franko J, Feng W, Yip L, Genovese E, Moser AJ. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology and outcomes in 2,158 patients. J Gastrointest Surg 2010;14:541-8.
2. Bilimoria KY, Bentrem DJ, Merkow RP, et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007;205:558-63.
3. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;11:2633-42.
4. Ballian N, Loeffler AG, Rajamanickam V, Norstedt PA, Weber SM, Cho CS. A simplified prognostic system for resected pancreatic neuroendocrine neoplasms. HPB 2009;11:422-8.
5. Exocrine and endocrine pancreas. In: Edge SB, Fritz AG, Byrd DR, et al, editors. AJCC cancer staging manual, 7th ed. Springer: New York; 2010:241-9.
6. Pelosi G, Bresaola E, Bogina G, et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index and other clinicopathologic variables. Hum Pathol 1996;27: 1124-34.
7. Jamali M, Chetty R. Predicting prognosis in gastroenteropancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol 2008;19:282-8.
8. Ehehalt F, Saeger HD, Schmidt CM, Grutzmann R. Neuroendocrine tumors of the pancreas. Oncologist 2009;14: 456-67.
9. Martin RCG, Kooby DA, Weber SM, et al. Analysis of 6,747 pancreatic neuroendocrine tumors for a proposed staging system. J Gastrointest Surg 2011;15:175-83.
10. Gentil-Perret A, Mosnier JF, Buono JO, et al. The relationship betweenMIB-1 proliferation index and outcomein pancreatic neuroendocrine tumors. Am J Clin Pathol 1998;109:286-93.
11. Vilar E, Salazar R, Perez-Garcia J, Cortes J, Oberg K, Tabernero J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocrine-Related Cancer 2007;14:221-32.